Art. -Nr.: HY-N0894

Octahydrocurcumin

(Synonyms: Hexahydrobisdemethoxycurcumin)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the TAK1-NF-κB-COX-2 pathway, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.25%
CAS. Nr.: 36062-07-4
Formel: C₂₁H₂₈O₆
Molecular Weight:376.44

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Octahydrocurcumin Chemical Structure

CAS. Nr.: 36062-07-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

COX-2

TAK1

Alle MAP4K Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle COX Isoform-spezifische Produkte anzeigen :

In Vivo

Octahydrocurcumin (5-20 mg/kg; i.g.; daily; 7 days) exerts potent dose-dependent anti-HCC activity in H22 ascites tumor-bearing mice, with 20 mg/kg OHC increasing survival by 78.98%, reducing ascites volume and cancer cell viability, inducing apoptosis, and modulating mitochondrial pathway-related proteins more effectively than 100 mg/kg curcumin, without immune organ toxicity^[1].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits xylene-induced mouse ear edema, achieving a maximum suppression rate of 70.67% at 40 mg/kg^[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently reduces acetic acid-induced vascular permeability in mice, reaching a 48.0% suppression rate at 40 mg/kg^[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits Carrageenan (HY-125474)-induced mouse paw edema, reduces pro-inflammatory mediator production, selectively suppresses COX-2 expression, and blocks the TAK1-NF-κB pathway^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming (KM) (male, 18-22 g, intraperitoneal injection of H22 cell suspension to establish HCC ascites model)^[1]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

i.g.; daily; 7 days
Result:

Increased survival rates by 26.13%, 50%, and 78.98% respectively compared to vehicle control; 20 mg/kg dose resulted in a significantly higher survival rate than 100 mg/kg curcumin.
Suppressed increases in body weight and abdominal circumference compared to vehicle control; 20 mg/kg dose resulted in significantly lower body weight and abdominal circumference than 100 mg/kg curcumin on day 7.
Showed no significant difference in spleen and thymus indexes compared to intact, vehicle, and curcumin groups at 20 mg/kg dose.
Reduced ascites volume significantly more than 100 mg/kg curcumin at 20 mg/kg dose.
Reduced cancer cellular viability significantly more than 100 mg/kg curcumin at 20 mg/kg dose.
Significantly increased the apoptotic rate of ascitic cells compared to 100 mg/kg curcumin at 20 mg/kg dose.
Upregulated p53, Bax, Bad, cytochrome C, cleaved caspase-9, cleaved caspase-3, and cleaved PARP protein expressions, and downregulated MDM2, Bcl-2, and Bcl-xl protein expressions to a greater extent than 100 mg/kg curcumin at 20 mg/kg dose; also upregulated Bax mRNA and downregulated Bcl-2 mRNA expression.

Animal Model:

ICR mice (male and female, 18-22 g)^[2]
Dosage:

10 mg/kg; 20 mg/kg; 40 mg/kg
Administration:

i.g.; daily; 7 days
Result:

Inhibited ear edema with suppression rates of 37.33%, 57.33%, and 70.67% at 10, 20, and 40 mg/kg, respectively.\nInhibited vascular permeability with a maximum suppression ratio of 48.0% at 40 mg/kg.\nAttenuated paw edema dose-dependently from 1 to 6 hours post-carrageenan injection.
Exhibited edema inhibition ratios of 35.87% at 4 hours, 45.16% at 5 hours, and 53.41% at 6 hours at 40 mg/kg.
Significantly reduced carrageenan-induced increases in IL-1β, IL-6, TNF-α, and PGE2 levels at 40 mg/kg, with greater inhibitory activity than curcumin.
Selectively downregulated COX-2 gene and protein expression without affecting COX-1 at 40 mg/kg.
Inhibited TAK1 phosphorylation, reduced TAB1 protein expression, suppressed IKKβ and IκBα phosphorylation, and prevented NF-κB (p65) translocation from the cytosol to the nucleus at 40 mg/kg.

Chemical Information

CAS. Nr. 36062-07-4
Appearance Solid-Liquid Mixture
Molecular Weight 376.44
Formel C₂₁H₂₈O₆
Color Light yellow to yellow
SMILES

OC(CC(O)CCC1=CC=C(O)C(OC)=C1)CCC2=CC=C(O)C(OC)=C2
Synonyms

Hexahydrobisdemethoxycurcumin
Structure Classification
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

University of Edinburgh

2025 May 29.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (265.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (26.56 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6565 mL

13.2823 mL

26.5647 mL

5 mM

0.5313 mL

2.6565 mL

5.3129 mL

10 mM

0.2656 mL

1.3282 mL

2.6565 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution

This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution

This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution

This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang Z , et al. Octahydrocurcumin, a final hydrogenated metabolite of curcumin, possesses superior anti-tumor activity through induction of cellular apoptosis. Food Funct. 2018;9(4):2005-2014. [Content Brief]

[2]. Zhang ZB, et al. Curcumin's Metabolites, Tetrahydrocurcumin and Octahydrocurcumin, Possess Superior Anti-inflammatory Effects in vivo Through Suppression of TAK1-NF-κB Pathway. Front Pharmacol. 2018;9:1181. Published 2018 Oct 17. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.6565 mL	13.2823 mL	26.5647 mL	66.4116 mL
	5 mM	0.5313 mL	2.6565 mL	5.3129 mL	13.2823 mL
	10 mM	0.2656 mL	1.3282 mL	2.6565 mL	6.6412 mL
	15 mM	0.1771 mL	0.8855 mL	1.7710 mL	4.4274 mL
	20 mM	0.1328 mL	0.6641 mL	1.3282 mL	3.3206 mL
	25 mM	0.1063 mL	0.5313 mL	1.0626 mL	2.6565 mL
DMSO	30 mM	0.0885 mL	0.4427 mL	0.8855 mL	2.2137 mL
	40 mM	0.0664 mL	0.3321 mL	0.6641 mL	1.6603 mL
	50 mM	0.0531 mL	0.2656 mL	0.5313 mL	1.3282 mL
	60 mM	0.0443 mL	0.2214 mL	0.4427 mL	1.1069 mL
	80 mM	0.0332 mL	0.1660 mL	0.3321 mL	0.8301 mL
	100 mM	0.0266 mL	0.1328 mL	0.2656 mL	0.6641 mL

Octahydrocurcumin

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Octahydrocurcumin

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Octahydrocurcumin

Alle MAP4K Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle COX Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Octahydrocurcumin Related Classifications

HY-N0894 Related Classifications